Mostrando 10 resultados de: 20
Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer
ArticleAbstract: An epidermal growth factor (EGF) vaccine was given before and after standard first line chemotherapyPalabras claves:cancer vaccine, EGF, NSCLCAutores:Bárbara Wilkinson, Carmen Elena Viada, Fleites G., González G., González M.J., Lage Davila A., Leonard I., Mazorra Z., Neninger Vinageras E., Pereda S., Tania Crombet, Verdecia B.G.Fuentes:scopusAssociations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer
ArticleAbstract: Aging is considered the single most significant risk factor for the majority of common malignances iPalabras claves:B cells, Epidermal growth factor, Pro-inflammatory cytokines, T cells, terminally differentiated T cellsAutores:Añe-Kouri A.L., Catala M., Cordero L., García Verdecia B., González A., Lage Davila A., Ledón N., Luaces P.L.o., Mazorra Z., Neninger Vinageras E., Pereira K., Saavedra Hernández D., Salomón E.E., Sánchez M.G., Suárez G.M., Tania CrombetFuentes:scopusBiomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients
ArticleAbstract: Purpose: There are well-known alterations occurring within the immune system with aging. CollectivelPalabras claves:cancer vaccine, Immunosenescence, Immunosenescence markers, Non-small cell lung cancerAutores:Fuentes K.P., García Verdecia B., González A., Lage Davila A., Luaces P.L.o., Mazorra Z., Neninger Vinageras E., Popa X., Saavedra Hernández D., Tania CrombetFuentes:scopusAnti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule
ArticleAbstract: We previously reported that CIMAvax-EGF vaccine is safe, immunogenic and efficacious to treat advancPalabras claves:antibodies affinity, cancer vaccine, EGF, NSCLC, surrogate biomarkerAutores:Alvarez K., Carmen Elena Viada, Fuentes K.P., García Verdecia B., González A., Gonzalez Z., Huerta V., Mazorra Z., Neninger Vinageras E., Popa X., Rodríguez P.C., Tania CrombetFuentes:scopusA Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
ArticleAbstract: Purpose: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvPalabras claves:Autores:Acosta S.C., Aguilera N., Alonso L., Amador R.M., Arzuaga L., Cala M., Carmen Elena Viada, Catala M., Crespo T., De La Torre A.V., Fleytas R., Flores Y.I., Futiel N., García Verdecia B., Lage Davila A., Luaces P.L.o., Marrero Miragaya M.A., Martínez O., Mazorra Z., Mendoza S., Neninger Vinageras E., Otero Y., Parra J., Pomares Y., Popa X., Reyes D., Rodríguez G., Rodríguez P.C., Romero G.N., Sabates T., Santiesteban E.R., Sierra P., Tania Crombet, Vello L.Fuentes:scopusCIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer
ReviewAbstract: Epidermal growth factor receptor (EGFR) is overexpressed in many epithelial tumors and its role in tPalabras claves:cancer vaccine, clinical trials, Epidermal growth factor, Epidermal growth factor receptor, lung cancer, Non-small-cell lung cancerAutores:García Verdecia B., Lage Davila A., Neninger Vinageras E., Rodríguez P.C., Tania CrombetFuentes:scopusCIMAvax-EGF: A novel therapeutic vaccine for advanced lung cancer
ArticleAbstract: The results allowing the Cuban Regulatory Agency (CECMED) to grant the Sanitary Registration to thePalabras claves:cancer vaccine, CIMAvax-EGF, Fast-Track registration, NSCLC, Phase II-III clinical trialAutores:Arteaga N., Cuevas A., García Verdecia B., González G., Lage Davila A., Neninger Vinageras E., Rodríguez G., Tania Crombet, Viña L.Fuentes:scopusCIMAvax-EGF: Toward long-term survival of advanced NSCLC
ReviewAbstract: Lung cancer remains one of the leading causes of cancer-related deaths. Non–small cell lung cancer (Palabras claves:cancer vaccine, CIMAvax-EGF, Clinical trial, EGF, Epidermal growth factor receptor, immunotherapy, non–small cell lung cancerAutores:Camilo Rodríguez, Carmen Elena Viada, Lage Davila A., Mazorra Z., Neninger Vinageras E., Saavedra Hernández D., Tania CrombetFuentes:scopusActive immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: Report of a phase I trial
ArticleAbstract: 1E10 is an anti-idiotype murine monoclonal antibody (Ab2 MAb) specific to an Ab1 MAb which reacts wiPalabras claves:Anti-idiotype antibody, Cancer Vaccines, Clinical study, immunotherapyAutores:Alfonso A.M., Alonso D.F., Bárbara Wilkinson, Combet T., De La Torre A.V., Díaz A., Díaz R.M., Gabri M.R., Neninger Vinageras E., Pérez R., Rives R., Saurez G., Vázquez A.M.Fuentes:scopusEpidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy
ArticleAbstract: Background: The role that growth factors and their receptors play in human cancer growth and progresPalabras claves:cancer vaccine, Epidermal growth factor, Non-small-cell lung cancerAutores:Alfonso L., Catala M., García Verdecia B., González G., Lage R., Mulet A., Neninger Vinageras E., Osorio M., Pérez R., Tania Crombet, Torres F.Fuentes:scopus